Gilead Sciences (GILD) Competitors

In the previous week, Gilead Sciences had 12 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 27 mentions for Gilead Sciences and 15 mentions for Ligand Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.75 beat Ligand Pharmaceuticals' score of 0.53 indicating that Gilead Sciences is being referred to more favorably in the news media.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Gilead Sciences' net margin of -10.64%. Ligand Pharmaceuticals' return on equity of 20.06% beat Gilead Sciences' return on equity.

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Ligand Pharmaceuticals presently has a consensus price target of $337.00, suggesting a potential upside of 12.69%. Gilead Sciences has a consensus price target of $158.78, suggesting a potential upside of 6.07%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Gilead Sciences.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

In the previous week, Moderna had 14 more articles in the media than Gilead Sciences. MarketBeat recorded 41 mentions for Moderna and 27 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.75 beat Moderna's score of 0.23 indicating that Gilead Sciences is being referred to more favorably in the news media.

Gilead Sciences has a net margin of -10.64% compared to Moderna's net margin of -141.43%. Gilead Sciences' return on equity of -2.11% beat Moderna's return on equity.

Moderna has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Moderna. Gilead Sciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Moderna presently has a consensus target price of $76.72, indicating a potential downside of 60.62%. Gilead Sciences has a consensus target price of $158.78, indicating a potential upside of 6.07%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Moderna.

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.2%. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Regeneron Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

In the previous week, Gilead Sciences had 11 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 27 mentions for Gilead Sciences and 16 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.83 beat Gilead Sciences' score of 0.75 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Regeneron Pharmaceuticals presently has a consensus target price of $802.18, suggesting a potential upside of 0.77%. Gilead Sciences has a consensus target price of $158.78, suggesting a potential upside of 6.07%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Gilead Sciences' net margin of -10.64%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Gilead Sciences' return on equity.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vir Biotechnology has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Gilead Sciences has a net margin of -10.64% compared to Vir Biotechnology's net margin of -638.88%. Gilead Sciences' return on equity of -2.11% beat Vir Biotechnology's return on equity.

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Gilead Sciences has higher revenue and earnings than Vir Biotechnology. Gilead Sciences is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Vir Biotechnology presently has a consensus target price of $21.57, suggesting a potential upside of 101.23%. Gilead Sciences has a consensus target price of $158.78, suggesting a potential upside of 6.07%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, research analysts plainly believe Vir Biotechnology is more favorable than Gilead Sciences.

In the previous week, Gilead Sciences had 26 more articles in the media than Vir Biotechnology. MarketBeat recorded 27 mentions for Gilead Sciences and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.67 beat Gilead Sciences' score of 0.75 indicating that Vir Biotechnology is being referred to more favorably in the media.